Financial Results with Results Press Release & Limited Review for June 30, 2013
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE about the Financial Results, Results Press Release & a copy of the Limited Review Report for the period ended June 30, 2013. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
R Vijayalakshmi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Approval for extension of Financial Year for 2012-2013 upto 18 Months
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that the Registrar of Companies (RoC), Chennai, Tamil Nadu has granted permission vide Order dated July 09, 2013 allowing the extension of financial year 2012-13 of the Company by a period of 6 (six) months i.e. upto September 30, 2013.Accordingly, the Annual Accounts of the Company for the financial year 2012-2013 shall be prepared for a period of 18 (eighteen) months from April 01, 2012 to September 30, 2013. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao, R Vijayalakshmi & Orchid Health Care Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Extension of Financial Year for 2012-2013 up to 18 Months
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company through circular resolution passed on June 24, 2013 have approved the extension of financial year 2012-2013 of the Company by a further period of 3 (three) months i.e. upto September 30, 2013, subject to the approval of the Registrar of Companies, Chennai.... Reference to CDR Cell (Corporate Debt Restructuring Scheme)
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that due to continuing liquidity constraints and pressure on operations, Orchid has initiated the process of restructuring its debt and accordingly the Company has made reference to the Corporate Debt Restructuring Cell (CDR Cell) through State Bank of India. Updates
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that Orchids Oral Formulations facility at Irungattukottai near Chennai was successfully inspected and accepted by the USFDA without any observations. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao, R Vijayalakshmi & Orchid Health Care Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Financial Results with Results Press Release & Limited Review for March 31, 2013
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE about the Financial Results, Results Press Release & a copy of the Limited Review Report for the period ended March 31, 2013. Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE regarding a Press Release dated April 18, 2013, titled "Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics"